Top Analysts Recommend Biopharma and Biotech Stocks with High Upside Potential
Wall Street's top analysts have identified Inventiva (IVA) and Nurix Therapeutics (NRIX) as strong buys, citing significant upside potential. Inventiva, a French biopharma firm focused on NASH treatments, holds a consensus 243.58% price target increase across seven analysts. Stifel Nicolaus reaffirmed its $17 target yesterday.
Nurix Therapeutics, developing cancer therapies, received a maintained $27 price target from Needham today. Three other analysts echo the bullish sentiment. These picks emerge as markets show renewed appetite for high-growth biotech plays.